Literature DB >> 15710544

Effects of hyperbaric oxygen on Leishmania amazonensis promastigotes and amastigotes.

Wagner Weber Arrais-Silva1, Marcelle Carolina Collhone, Diana Copi Ayres, Paula Cristina de Souza Souto, Selma Giorgio.   

Abstract

In the present study, we evaluated the effects of hyperbaric oxygen (HBO) exposure in both Leishmania amazonensis life stages (promastigotes and amastigotes) and on macrophage cultures infected with the parasite. HBO treatment protocols, which can be tolerated by humans and animals, induced irreversible metabolic damage and affected parasite morphology, growth and ability to transform. The observation that the antioxidant N-acetylcysteine (NAC) prevents some of these deleterious effects indicated an involvement of oxidative stress during parasite HBO exposure. In addition, HBO exposed L. amazonensis-infected macrophage cultures showed reduction of the percentage of infected cells and of the number of intracellular parasites per cell. Thus, the demonstration that HBO, a therapy used in the management of different diseases, is toxic for both L. amazonensis life stages and can alter macrophage susceptibility to the infection encourages further studies of this therapy in animal models of Leishmania infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710544     DOI: 10.1016/j.parint.2004.07.002

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  8 in total

1.  Expression and Characterization of Glucose Oxidase from Aspergillus niger in Yarrowia lipolytica.

Authors:  Fatemeh Khadivi Derakshan; Farshad Darvishi; Mehrouz Dezfulian; Catherine Madzak
Journal:  Mol Biotechnol       Date:  2017-08       Impact factor: 2.695

2.  Synthesis and evaluation of the antileishmanial activity of silver compounds containing imidazolidine-2-thione.

Authors:  Patrícia Ferreira Espuri; Larissa Luiza Dos Reis; Eduardo de Figueiredo Peloso; Vanessa Silva Gontijo; Fábio Antônio Colombo; Juliana Barbosa Nunes; Carine Ervolino de Oliveira; Eduardo T De Almeida; Débora E S Silva; Jessica Bortoletto; Daniel Fonseca Segura; Adelino V G Netto; Marcos José Marques
Journal:  J Biol Inorg Chem       Date:  2019-04-04       Impact factor: 3.358

Review 3.  Pathophysiological Mechanisms in Gaseous Therapies for Severe Malaria.

Authors:  Ana Carolina A V Kayano; João Conrado K Dos-Santos; Marcele F Bastos; Leonardo J Carvalho; Júlio Aliberti; Fabio T M Costa
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

4.  A novel organotellurium compound (RT-01) as a new antileishmanial agent.

Authors:  Camila Bárbara Cantalupo Lima; Wagner Welber Arrais-Silva; Rodrigo Luiz Oliveira Rodrigues Cunha; Selma Giorgio
Journal:  Korean J Parasitol       Date:  2009-08-28       Impact factor: 1.341

5.  HSP70 of Leishmania amazonensis alters resistance to different stresses and mitochondrial bioenergetics.

Authors:  Bárbara Santoni Codonho; Solange Dos Santos Costa; Eduardo de Figueiredo Peloso; Paulo Pinto Joazeiro; Fernanda Ramos Gadelha; Selma Giorgio
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-06-10       Impact factor: 2.743

6.  Effects of hyperbaric oxygen and N-acetylcysteine in survival of random pattern skin flaps in rats.

Authors:  Fernando P da Rocha; Djalma J Fagundes; Jefferson A Pires; Fernanda Salim T da Rocha
Journal:  Indian J Plast Surg       Date:  2012-09

7.  Hyperbaric oxygen prevents early death caused by experimental cerebral malaria.

Authors:  Yara C Blanco; Alessandro S Farias; Uta Goelnitz; Stefanie C P Lopes; Wagner W Arrais-Silva; Bruna O Carvalho; Rogério Amino; Gerhard Wunderlich; Leonilda M B Santos; Selma Giorgio; Fabio T M Costa
Journal:  PLoS One       Date:  2008-09-04       Impact factor: 3.240

8.  The Anti-leishmanial Efficacy of Artemisia dracunculus Ethanolic Extract in Vitro and Its Effects on IFN-γ and IL-4 Response.

Authors:  Reza Rezaei; Khosrow Hazrati Tappeh; Shahram Seyyedi; Peyman Mikaili
Journal:  Iran J Parasitol       Date:  2017 Jul-Sep       Impact factor: 1.012

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.